AXSM Axsome Therapeutics, Inc.

4.18
-0.13  -2.91%
Previous Close 4.30
Open 4.40
Price To book 2.92
Market Cap 79.96M
Shares 19,153,000
Volume 63,293
Short Ratio 6.37
Av. Daily Volume 40,369

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 to be initiated 1H 2017.
AXS-05
Agitation in patients with Alzheimer’s disease (AD)
Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 1Q or 2Q 2017.
AXS-02
Complex regional pain syndrome (CRPS)
Phase 3 initiated March 2016. Continues to enroll as of November 2016.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 commenced March 2016. Continues to enroll as of November 2016.
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 planned. IND to be filed by end of 2016.
AXS-02
Chronic Low Back Pain Associated with Modic Changes

Latest News

  1. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  2. Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant Depression
  3. Axsome Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference
  4. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  5. Axsome Therapeutics to Present at the 2017 BIO CEO & Investor Conference
  6. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  7. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  8. Axsome Therapeutics to Present at Biotech Showcase 2017
  9. Axsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
  10. AXSOME THERAPEUTICS, INC. Financials
  11. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  12. AXSOME THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  13. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ
  14. Anavex Life Sciences Joins The Club Of Stocks Moving Higher On News Of Alzheimer's Research
  15. Axsome Therapeutics: Teaching Old Drugs New Tricks
  16. 5 Stocks Under $10 Poised for Big Breakouts
  17. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Stat
  18. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  19. AXSOME THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  20. AXSOME THERAPEUTICS, INC. Files SEC form 10-Q/A, Quarterly Report